Correlation Between Cue Biopharma and Eyenovia
Can any of the company-specific risk be diversified away by investing in both Cue Biopharma and Eyenovia at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cue Biopharma and Eyenovia into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cue Biopharma and Eyenovia, you can compare the effects of market volatilities on Cue Biopharma and Eyenovia and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cue Biopharma with a short position of Eyenovia. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cue Biopharma and Eyenovia.
Diversification Opportunities for Cue Biopharma and Eyenovia
-0.06 | Correlation Coefficient |
Good diversification
The 3 months correlation between Cue and Eyenovia is -0.06. Overlapping area represents the amount of risk that can be diversified away by holding Cue Biopharma and Eyenovia in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eyenovia and Cue Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cue Biopharma are associated (or correlated) with Eyenovia. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eyenovia has no effect on the direction of Cue Biopharma i.e., Cue Biopharma and Eyenovia go up and down completely randomly.
Pair Corralation between Cue Biopharma and Eyenovia
Considering the 90-day investment horizon Cue Biopharma is expected to generate 0.41 times more return on investment than Eyenovia. However, Cue Biopharma is 2.44 times less risky than Eyenovia. It trades about -0.17 of its potential returns per unit of risk. Eyenovia is currently generating about -0.25 per unit of risk. If you would invest 175.00 in Cue Biopharma on August 31, 2024 and sell it today you would lose (53.00) from holding Cue Biopharma or give up 30.29% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Cue Biopharma vs. Eyenovia
Performance |
Timeline |
Cue Biopharma |
Eyenovia |
Cue Biopharma and Eyenovia Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Cue Biopharma and Eyenovia
The main advantage of trading using opposite Cue Biopharma and Eyenovia positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cue Biopharma position performs unexpectedly, Eyenovia can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyenovia will offset losses from the drop in Eyenovia's long position.Cue Biopharma vs. Coya Therapeutics, Common | Cue Biopharma vs. Lantern Pharma | Cue Biopharma vs. Fennec Pharmaceuticals | Cue Biopharma vs. Eliem Therapeutics |
Eyenovia vs. Reviva Pharmaceuticals Holdings | Eyenovia vs. Cidara Therapeutics | Eyenovia vs. Fortress Biotech | Eyenovia vs. Reviva Pharmaceuticals Holdings |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Complementary Tools
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |